6:25 PM
 | 
Nov 10, 2015
 |  BC Extra  |  Clinical News

AZ reports Phase II SLE data

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said the lower of two doses of anifrolumab ( MEDI-546) showed a statistically significant improvement on the primary endpoint in a Phase II trial to treat moderate to severe systemic lupus erythematosus. Data for the human mAb targeting type I interferon (IFN) receptor 1 were presented at the American College of Rheumatology meeting...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >